Haemonetics (HAE) Other Accumulated Expenses (2010 - 2026)

Haemonetics has reported Other Accumulated Expenses for 17 years, with the latest figure at $158.3 million in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses rose 6.89% year-over-year to $158.3 million; the trailing twelve-month figure through Mar 2026 stood at $158.3 million (up 6.89% YoY), and the FY2026 full-year result was $158.3 million, up 6.89% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $158.3 million, up from $134.3 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $158.3 million in Q1 2026, with the low at $85.3 million in Q3 2022.
• Average Other Accumulated Expenses over 5 years is $127.3 million, with a median of $133.2 million recorded in 2023.
• Year-over-year, Other Accumulated Expenses slumped 33.26% in 2022 and jumped 31.6% in 2023.
• Tracing HAE's Other Accumulated Expenses over 5 years: stood at $101.0 million in 2022, then jumped by 31.12% to $132.4 million in 2023, then grew by 5.15% to $139.2 million in 2024, then dropped by 3.52% to $134.3 million in 2025, then gained by 17.87% to $158.3 million in 2026.
• The last three Other Accumulated Expenses figures came in at $158.3 million (Q1 2026), $134.3 million (Q4 2025), and $134.0 million (Q3 2025), per Business Quant data.

Peer Comparison